eShowcase: TrialSpace Designer
Tools for Clinical Trials Professionals
Package integrates smoothly into existing business enterprise software formats
Fast Track Systems Inc. (Conshohocken, PA) has a new enterprise solution for advancing the clinical development process. According to Fast Track Systems, TrialSpace Designer improves quality by ensuring protocol consistency and accuracy, and eliminates operational ambiguities at the trial design stage.
The solution is tailored to a life science company's specific therapeutic areas to adhere to individual corporate processes, SOPs, and standard text, plus it incorporates existing Word templates. With TrialSpace Designer, clinical trial professionals have access to indication-specific industry benchmark data on procedures and costs from the company's proprietary databases. Fast Track Systems says that the package delivers better operational efficiency with faster trial startup and completion and reduces avoidable operational costs. Among other benefits are quicker and cleaner trial summations for regulatory submissions and shorter trial timelines.
TrialSpace Designer
Fast Track Systems Inc., (215) 358-1400, www.fast-track.com
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
